MetaVia Inc. Files 8-K Report

TL;DR

MetaVia Inc. filed a standard 8-K, mostly procedural with exhibits.

AI Summary

On December 18, 2024, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates MetaVia Inc. is fulfilling its regulatory reporting obligations with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events, risks, or financial changes.

Key Players & Entities

• MetaVia Inc. (company) — Registrant
• NeuroBo Pharmaceuticals, Inc. (company) — Former company name
• Gemphire Therapeutics Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share MTVA The Nasdaq Stock Mar

Filing Documents

• mtva-20241218x8k.htm (8-K) — 46KB
• mtva-20241218xex99d1.htm (EX-99.1) — 102KB
• mtva-20241218x8k001.jpg (GRAPHIC) — 9KB
• mtva-20241218xex99d1001.jpg (GRAPHIC) — 16KB
• 0001558370-24-016344.txt ( ) — 325KB
• mtva-20241218.xsd (EX-101.SCH) — 3KB
• mtva-20241218_lab.xml (EX-101.LAB) — 16KB
• mtva-20241218_pre.xml (EX-101.PRE) — 10KB
• mtva-20241218x8k_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure . On December 18, 2024, MetaVia Inc. (the "Company") issued a press release announcing positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated December 18, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METAVIA INC. Date: December 18, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR